SURFAXIN® Treatment for Prevention of Bronchopulmonary Dysplasia (BPD) in Very Low Birth Weight (VLBW) Infants.

NCT00215540 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

136

Enrollment

INDUSTRY

Sponsor class

Stopped Concerns related to availability of drug product

Conditions

Respiratory Distress Syndrome, Newborn
Premature Birth
Bronchopulmonary Dysplasia

Interventions

DRUG: Lucinactant 175 mg/kg
DRUG: Lucinactant 90 mg/kg
DRUG: Placebo

Sponsor

Windtree Therapeutics